Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Dr. Marie Paule Richard, Chief Medical Officer of TiGenix, will be speaking at the 7th TERMIS-EU Industry Day taking place from June 26-30, 2017 at the Davos Conference Center, Switzerland.
Mithra Pharmaceuticals SA, a company specialized in Women’s Health, announces that it has successfully raised €26.1 million in gross proceeds by means of a private placement of new shares via an accelerated bookbuild offering.
Celyad SA (EURONEXT Brussels and Paris: CYAD – NASDAQ Global Market: CYAD), a leader in the discovery and development of CAR-T cell therapies, today announces it has published a special report in the peer-reviewed journal “Future Oncology” summarizing pre-clinical work undertaken on NKR-2, the CAR-T cell therapy currently tested in the company’s THINK trial.
EFRO Vlaanderen en Bio Base Europe Pilot Plant (BBEPP) ondertekenden een overeenkomst voor een investering van 9,36 miljoen EURO in het kader van het IMPACT project. Deze investering wordt gedragen door het Europees Fonds voor Regionale Ontwikkeling (EFRO), Vlaanderen, de Provincie Oost-Vlaanderen, de Stad Gent en de Bio Base Europe Pilot Plant. Hiermee zal nieuwe onderzoeksinfrastructuur worden opgebouwd, specifiek voor gasfermentatie en Down-Stream Processing.
The Ghent-based life sciences consultancy firm pi is proud to announce partnerships with both the Alzheimer Liga Vlaanderen and the Ligue Alzheimer ASBL. The partnerships will focus on personal support towards the people diagnosed with early onset dementia, their caregivers and family as well as supporting events concerning early-onset dementia and raising awareness amongst the community.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.
UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.